PDCD1 and non-small cell lung carcinoma: Checkpoint inhibitor-based immunotherapy targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has acquired a central role in the management of patients with locally advanced or metastatic driver-negative NSCLC.